Document is current

Any future updates will be listed below

Results from a 78‐week, single‐arm, open‐label phase 2 study to evaluate UX007 in pediatric and adult patients with severe long‐chain fatty acid oxidation disorders (LC‐FAOD)

Crossref DOI link: https://doi.org/10.1007/s10545-018-0217-9

Published Online: 2019-02-11

Published Print: 2019-01

Update policy: https://doi.org/10.1002/crossmark_policy

About CrossMark